KR

Kit Rees

Person

Kit Rees is a Bloomberg reporter who covers financial markets and business news. She frequently analyzes and discusses major European stock movements.

What Kit Rees has said on podcasts

9 statements

  1. on AstraZenecaNegativeAug 17, 2026· Stock Movers

    AstraZeneca shares are currently depressed relative to their level since July.

    “AstraZeneca shares are pretty depressed since July really”

    Listen at 1:41

    Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx Surges
  2. on AI-driven copper demandPositiveAug 17, 2026· Stock Movers

    AI has been a major driver of copper demand this year.

    “AI has been the big demand driver this year”

    Listen at 2:20

    Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx Surges
  3. on CopperPositiveAug 17, 2026· Stock Movers

    Copper is a key component used in data centers.

    “It's used in data centers. So it's a really, really key component.”

    Listen at 2:24

    Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx Surges
  4. on Copper demandPositiveAug 17, 2026· Stock Movers

    Demand for copper is currently very high.

    “there's just a huge demand for copper”

    Listen at 2:32

    Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx Surges
  5. on US-bound copper shipmentsPositiveAug 17, 2026· Stock Movers

    US-bound copper shipments are supporting mining companies’ share prices.

    “this is just really buoying these mining companies”

    Listen at 2:42

    Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx Surges
  6. on argenx experimental myositis treatmentPositiveAug 17, 2026· Stock Movers

    argenx reported positive trial results for an experimental myositis treatment.

    “it had a slatestail trial results for experimental treatment for myositis”

    Listen at 3:06

    Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx Surges
  7. on Biotech stocksMixedAug 17, 2026· Stock Movers

    Biotech stocks can experience highly binary outcomes.

    “biotech stocks, they can be a little bit binary”

    Listen at 3:14

    Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx Surges
  8. on Biotech stocksMixedAug 17, 2026· Stock Movers

    Biotech stocks’ fortunes depend on whether particular drugs succeed in development.

    “their fortunes really depend on whether a particular drug is successful in its development”

    Listen at 3:17

    Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx Surges
  9. on argenx sharesPositiveAug 17, 2026· Stock Movers

    argenx shares are up approximately 10% year-to-date.

    “the shares are now positive on the year. They're up about 10%”

    Listen at 3:28

    Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx Surges

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

1 episode featuring Kit Rees

What is PodLume?

PodLume turns podcasts into searchable knowledge. AI-decoded transcripts, identified guests and topics, smart highlights, and cross-show search across the world’s best conversations — all in your pocket.

Kit Rees | PodLume